Detection of CBF beta/MYH11 fusion transcript: Value of minimal residual disease follow-up

被引：0
|
作者：
Costello, R
Cusenier, A
Sainty, D
Mozziconacci, MJ
Arnoulet, C
Blaise, D
Novakovitch, G
Maraninchi, D
Gastaut, JA
LafagePochitaloff, M
Gabert, J
机构：
[1] CTR CANC,DEPT BIOL,F-13009 MARSEILLE,FRANCE
[2] CTR CANC,DEPT CLIN HEMATOL,F-13009 MARSEILLE,FRANCE
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 1996年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：825 / 825
页数：1
相关论文
共 50 条
  • [21] Long-term disease-free acute myeloblastic leukemia with inv(16) is associated with PCR undetectable CBFβ/MYH11 transcript
    Martinelli, G
    Ottavlani, E
    Testoni, N
    Montefusco, V
    Buonamici, S
    Tura, S
    HAEMATOLOGICA, 2000, 85 (05) : 552 - 554
  • [22] Prospective monitoring of minimal residual disease by polymerase chain reaction in patients with acute myeloid leukemia expressing CBF beta 1MYH11 fusion transcripts.
    Moos, M
    Schmohl, D
    Fischer, K
    Schlenk, R
    Diehl, D
    Haas, R
    Dohner, H
    BLOOD, 1996, 88 (10) : 2237 - 2237
  • [23] Defining the ''absence'' of the CBF beta/MYH11 fusion transcript in patients with acute myeloid leukemia and inversion of chromosome 16 to predict long-term complete remission: A call for definitions
    Marcucci, G
    Caligiuri, MA
    Bloomfield, CD
    BLOOD, 1997, 90 (12) : 5022 - 5024
  • [24] Real time RT-PCR for the detection and quantification of CBFβ/MYH11 fusion transcripts in INV(16) positive AML.
    Hoellge, W
    Wattjes, M
    Nagel, S
    Doden, M
    Krug, U
    Ganser, A
    Heil, G
    BLOOD, 1999, 94 (10) : 207B - 207B
  • [25] Quantification of CBF beta/MYH11 fusion transcripts by competitive RT-PCR potentially predicts patient outcome in AML with inv(16).
    Novak, M
    Laczika, K
    Hilgarth, B
    ScheidelPetrovic, A
    Mitterbauer, M
    Lechner, K
    Jaeger, U
    BLOOD, 1996, 88 (10) : 2236 - 2236
  • [26] Prognosis value of residual disease monitoring by polymerase chain reaction in patients with CBF beta/MYH11-positive acute myeloblastic leukemia
    Costello, R
    Sainty, D
    Blaise, D
    Gastaut, JA
    Gabert, J
    Poirel, H
    BuzynVeil, A
    Macintyre, E
    BLOOD, 1997, 89 (06) : 2222 - 2223
  • [27] Rare type I CBFβ/MYH11 fusion transcript in primary acute myeloid leukemia with inv(16)(p13.1q22): a case report
    Zhang, Wenyi
    Wang, Hainan
    Zhang, Peilei
    Li, Hongliang
    Ma, Xiaoli
    Liu, Hongxing
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2021, 54 (12)
  • [28] HETEROGENEITY IN CBF-BETA/MYH11 FUSION MESSAGES ENCODED BY INV(16) AND T(16-16) IN ACUTE MYELOGENOUS LEUKEMIA (AML)
    DOWNING, J
    SHURTLEFF, S
    MEYERS, S
    HIEBERT, S
    RAIMONDI, S
    HEAD, D
    WILLMAN, C
    WOLMAN, S
    CARROLL, A
    BEHM, F
    COLLINS, F
    LIU, P
    LABORATORY INVESTIGATION, 1995, 72 (01) : A109 - A109
  • [29] Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBF/MYH11 gene expression
    Zhao Xiaosu
    Cao Leqing
    Qin Yazhen
    Wang Yu
    Zhang Xiaohui
    Xu Lanping
    Huang Xiaojun
    Chang Yingjun
    ANNALS OF HEMATOLOGY, 2019, 98 (01) : 73 - 81
  • [30] Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBFβ/MYH11 gene expression
    Zhao Xiaosu
    Cao Leqing
    Qin Yazhen
    Wang Yu
    Zhang Xiaohui
    Xu Lanping
    Huang Xiaojun
    Chang Yingjun
    Annals of Hematology, 2019, 98 : 73 - 81
12345